madrid2i

Resumen

The present invention relates to amorphous form darifenacin hydrobromide and processes therefor. In addition, the present invention relates to compositions comprising amorphous form darifenacin hydrobromide.

Reivindicaciones

CLAIM(S): 1. Amorphous form darifenacin hydrobromide. 2. Amorphous form darifenacin hydrobromide having an X-ray diffraction pattern (2Θ) as substantially shown in Figure 3. 3. Amorphous form darifenacin hydrobromide having an X-ray diffraction pattern (2Θ) having a characteristic broad X-ray diffraction maximum at about 10 to 35 degrees 2Θ. 4. A process for preparing amorphous darifenacin hydrobromide comprising: i) melting crystalline darifenacin hydrobromide, and ii) cooling the molten darifenacin hydrobromide to a temperature between about room temperature and about 0 <0>C, thereby forming amorphous darifenacin hydrobromide. 5. A process for preparing amorphous darifenacin hydrobromide comprising: i) providing darifenacin hydrobromide, and ii) dissolving darifenacin hydrobromide in a solvent, and iii) removing the solvent from said solution, thereby forming amorphous darifenacin hydrobromide. 6. The process of claim 5, wherein the solvent is selected from the group consisting of methanol, chloroform, dichloromethane, and mixtures thereof. 7. The process of claim 5, wherein the solvent is removed by evaporation. 8. The process of claim 5, wherein the solvent is removed by spray drying. 9. The process of claim 4, wherein the darifenacin hydrobromide used for preparing amorphous darifenacin is crystalline darifenacin hydrobromide. 10. The process of claim 5, wherein the darifenacin hydrobromide used for preparing amorphous darifenacin is crystalline darifenacin hydrobromide. 11. The process of claim 9, wherein the crystalline darifenacin hydrobromide is darifenacin hydrobromide crystalline Form I. 12. The process of claim 10, wherein the crystalline darifenacin hydrobromide is darifenacin hydrobromide crystalline Form I. 13. A process for preparing darifenacin hydrobromide crystalline Form I comprising exposing amorphous darifenacin hydrobromide at a relative humidity, temperature, and a period of time sufficient to convert amorphous darifenacin hydrobromide to darifenacin hydrobromide crystalline Form I. 14. The process of claim 13, wherein the relative humidity is about 75%. 15. The process of claim 13, wherein the temperature is about 40 <0>C. 16. The process of claim 13, wherein the period of time is about 14 days. 17. A pharmaceutical composition comprising amorphous darifenacin hydrobromide. 18. The process of claim 5, wherein the darifenacin hydrobromide is provided by an in situ conversion of darifenacin free base or other pharmaceutically acceptable salt of darifenacin to darifenacin hydrobromide.

Índice de la ficha

En detalle

Resumen

Reivindicaciones

Etiquetas